You are now leaving

Please click 'Continue to external site' if you want to continue.

Dr. Melanie Rolli

Group Chief Executive Officer


  • Joined Helsinn in June 2022 and appointed Group Chief Operating Officer
  • +20 years’ experience in the pharmaceutical and biotech sectors in executive and non-executive roles, general management, business & fundraising and vision & strategy development
  • Prior to Helsinn served as Chief Executive Officer at both AELIX Therapeutics and PIQUR Therapeutics, developing molecules in oncology and dermatology
  • 14 years at Novartis Pharma in various leadership roles across drug development and medical affairs, focused on oncology, including being an integral part of the GSK Oncology Portfolio Integration into Novartis Oncology Business Unit
  • Completed an MD at Heidelberg University, Germany and held a postdoctoral fellowship in cancer research at SCRIPPS Research Institute for Molecular and Experimental Medicine, USA.

Helsinn’s Senior Executive Committee Team

Riccardo Braglia

Executive Chairman

Konrad Wilson

Group Chief Financial Officer

Dr. Melanie Rolli

Group Chief Executive Officer

Giorgio Calderari

Vice Chairman

Matteo Missaglia

Group General Counsel, Group Chief Legal Officer

Sergio Cantoreggi

Group Chief Scientific Officer, Global Head of R&D

Georg Büchner

Group Chief Business Officer

Roberta Cannella

Group Chief Technical Operations Officer